US FDA Grants Emergency Approval for COVID-19 Convalescent Plasma Treatment (Update)

Second Treatment Approval Following Remdesivir
Use Authorized Within 3 Days of Diagnosis

[Asia Economy New York=Correspondent Baek Jong-min] The U.S. Food and Drug Administration (FDA) has granted emergency approval to use the plasma of recovered COVID-19 patients for treatment.

Medical staff are drawing blood to secure plasma from COVID-19 recovered patients. [Image source=Reuters Yonhap News]

According to the Wall Street Journal and others on the 23rd (local time), the FDA granted emergency approval for treatment using plasma from recovered COVID-19 patients just before President Donald Trump's briefing.

According to the Journal, under this FDA measure, plasma treatment for COVID-19 patients is allowed within 3 days of diagnosis. The Journal reported that until now, the only COVID-19 treatment approved by the FDA was Gilead's Remdesivir.

This content was produced with the assistance of AI translation services.